老虎證券

BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand Patient Access To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium

Reuters
2025/12/10
BRIEF-SCIENTURE And BlinkRx Announce Strategic Collaboration To Expand <a href="https://laohu8.com/S/PASO">Patient Access</a> To Arbli, The First FDA-Approved Ready-To-Use Oral Suspension Of Losartan Potassium

Dec 10 (Reuters) - Scienture Holdings Inc SCNX.O:

  • SCIENTURE AND BLINKRX ANNOUNCE STRATEGIC COLLABORATION TO EXPAND PATIENT ACCESS TO ARBLI™, THE FIRST FDA-APPROVED READY-TO-USE ORAL SUSPENSION OF LOSARTAN POTASSIUM

  • SCIENTURE HOLDINGS INC - ARBLI EXPECTED ON BLINKRX PLATFORM IN Q1 2026

Source text: ID:nGNX8zLbfl

Further company coverage: SCNX.O

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10